Despite falling short of Bloomberg's projections, Eris Lifesciences saw a stock boost following Macquarie’s reaffirmed ‘Outperform’ rating and ₹1680 target price. The company demonstrated substantial YoY growth in profit, EBITDA, and revenue.

• Macquarie maintains an ‘Outperform’ rating.
• Revenue grew 28% year over year.
• Profit increased 32% YoY.